Working with pharmaceuticalsWe’re pleased to work in partnership with pharmaceutical companies where such partnerships support our mission.
Bloodwise’s mission is to stop people dying from blood cancer, to make patients’ lives better, and to stop blood cancers happening in the first place. We are pleased to work in partnership with pharmaceutical companies where such partnerships support our mission.
The purpose of this policy is to provide clear principles and guidance about how Bloodwise works with pharmaceutical companies. Such partnerships enable us to achieve the charity’s mission, without compromising our integrity. This policy exists to ensure our work with pharmaceutical firms does not affect our ability to offer independent and unbiased patient information, or influence our campaigning, research or fundraising activities.
Bloodwise recognises that working with pharmaceutical companies that manufacture and market drugs and treatments gives Bloodwise important knowledge and expertise. Such companies are also willing to sponsor and fund certain activities undertaken by Bloodwise. However, pharmaceutical companies are not charitable organisations and Bloodwise takes particular care in how it works with them.
This Policy sets the principles which Bloodwise will adhere to when entering into partnerships with pharmaceutical firms and ensures that all partnerships are consistent with our organisational aims. These are as follows:
- All partnerships will be based on the principles of integrity and openness and will bring benefit to Bloodwise through funding or through supporting Bloodwise to achieve its mission.
- Bloodwise welcomes positive and transparent relationships with pharmaceutical companies
- All partnerships between pharmaceutical companies and Bloodwise including employee fundraising relationships will be subject to a full risk assessment and approval by the relevant Executive Team members.
- Any partnership entered into will not compromise the independent status of Bloodwise. When working with partners with a commercial interest in blood cancer we will, where linked to political or campaigning activities, seek to work with a minimum of two partners in order to maintain independence and impartiality.
- Bloodwise welcomes opportunities to raise funds and awareness through cause related marketing and sponsorship. However, Bloodwise will not directly endorse any third party, its products or services.
- Bloodwise will work with members of the pharmaceutical industry to ensure that findings from our insights into blood cancer patient need is taken into account and properly considered in drug development and access to new medicines. This might involve accepting sponsorship from the pharmaceutical company for the following activities:
- Speaking at and chairing meetings
- Training services
- Participation at advisory board meetings
- Participation in market research where such participation involves remuneration and/or travel. This applies when the company is aware of the identity of those participating in the market research
- Sponsorship in relation to attendance at meetings, which is registration fees and the costs of accommodation and travel.
- No commercial partnership will be entered into with a company whose product or service is considered to be detrimental to people living with blood cancer, or any product or service with unsupported claims of positive benefits to those with blood cancer. All partnerships with products and services with specific links to blood cancer will require approval by the Director of Research and Director of Patient Experience.
- Partnerships with pharmaceutical companies will not compromise Bloodwise independent status and will comply with the ABPI Code of Practice for the Pharmaceutical Industry
- Bloodwise will not accept support for activities which lie outside our objectives. Where possible we favour the use of a funding consortia based on two or more pharmaceutical companies working together. However, we will enter into strategic partnerships with individual companies if it is deemed to be in the best interest of those affected by blood cancer.
- There may be occasions where we will campaign for equitable access to a treatment. Under no circumstances will we accept funding from pharmaceutical companies to support campaigning activity for access to specific treatments. However, inevitably, there may be times when we will campaign for the availability of a treatment produced and promoted by a pharmaceutical company from which we have received funding in the past.
Following on from these principles, Bloodwise will only accept financial support from pharmaceutical firms in accordance with this policy, which will be reviewed on an annual basis.
Bloodwise already has a number of standard internal processes, activities and bodies that are of particular assistance in ensuring that relationships with pharmaceutical companies are effective. These processes enable Bloodwise to be user-led, evidence-based and work to high professional standards. They ensure we plan effectively, monitor and evaluate our activities, and have well-informed and robust governance.
In particular, this policy notes:
- the role of the Board of Trustees
- Core values
- Senior Management Team
- The risk register
- Process for reviewing publications, inc. external peer review
- Research Committee
- Medical Advisory Board
- User involvement, including our panel of Bloodwise Ambassadors
- Budgetary requirements
- Approval process for corporate partners
In addition to the above standard internal processes, activities and bodies the following conditions apply to pharmaceutical companies.
We will only work with pharmaceutical companies where:
- The activity being supported is within our strategic aims;
- The activity meets the criteria and conditions outlined in this policy.
- The relationship is not subject to any conditions that are unacceptable or conditions that prevent us from acting in the best interests of people with blood cancer. We will enter into written agreements with pharmaceutical companies with whom we work which document the agreed terms and conditions;
- We can ensure that our independence is maintained so that we are free to speak freely and comprehensively in a balanced way about pharmaceutical companies;
- We can ensure compliance with the conditions of the ABPI Code of Practice for the Pharmaceutical Industry. Where a company is not a member of the ABPI we will require written assurances that any partnership work or support will be conducted to the ABPI Code of Practice, with particular reference to the conditions that are the Bloodwise priorities for the activity;
- We can ensure that our editorial independence is maintained so that we are free to comment both positively and negatively about pharmaceutical companies and their products;
- We will not endorse or campaign for any specific product or drug.